Summary
IQQH Chart
iShares Global Clean Energy ETF Dividends
| INRG INRG In 4 months Estimated | Other | $0.04 Per Share |
| INRG INRG 1 month ago Paid | Other | $0.04 Per Share |
| INRG INRG 7 months ago Paid | Other | $0.06 Per Share |
| INRG INRG 16 May 2024 Paid | Other | $0.02 Per Share |
| INRG INRG 16 Nov 2023 Paid | Other | $0.04 Per Share |
| INRG INRG 19 May 2023 Paid | Other | $0.03 Per Share |
iShares Global Clean Energy ETF Earnings
| INRG INRG In 4 months Estimated | Other | $0.04 Per Share |
| INRG INRG 1 month ago Paid | Other | $0.04 Per Share |
| INRG INRG 7 months ago Paid | Other | $0.06 Per Share |
| INRG INRG 16 May 2024 Paid | Other | $0.02 Per Share |
| INRG INRG 16 Nov 2023 Paid | Other | $0.04 Per Share |
| INRG INRG 19 May 2023 Paid | Other | $0.03 Per Share |
iShares Global Clean Energy ETF (IQQH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has iShares Global Clean Energy ETF ever had a stock split?
iShares Global Clean Energy ETF Profile
| XSTU Exchange | Israel Country |
Overview
Can-Fite BioPharma Ltd. is an innovative clinical-stage biopharmaceutical company based in Ramat Gan, Israel, dedicated to the development of orally bioavailable small molecule therapeutic products. These products are aimed at treating a range of conditions including cancer, liver inflammatory diseases, and erectile dysfunction. Established in 1994 and originally named Can-Fite Technologies Ltd., the company underwent a name change to Can-Fite BioPharma Ltd. in January 2001, reflecting its specialized focus on biopharmaceuticals. With a strong commitment to addressing unmet medical needs, Can-Fite BioPharma has forged key collaborations, such as with CMS Medical for the development and commercialization of specific drug candidates and Univo Pharmaceuticals for the co-development of cannabis-based therapies for various diseases.
Products and Services
- Piclidenoson
An advanced drug candidate targeted primarily at psoriasis, Piclidenoson has successfully completed Phase III clinical trials. Its oral administration and bioavailability make it a promising treatment option for patients. Furthermore, Can-Fite BioPharma explores its potential in addressing other autoimmune and inflammatory diseases, underpinning the company's versatile approach to drug development.
- Namodenoson
This promising compound is undergoing Phase III clinical trials for liver cancer treatment and Phase IIa for pancreatic cancer, illustrating its potential in combating some of the most challenging cancer types. Additionally, it is in a Phase IIb trial for metabolic associated steatohepatitis (MASH), showcasing the diverse applicability of Namodenoson in treating various severe conditions.
- CF602
Still in the pre-clinical trial stage, CF602 is being developed to address erectile dysfunction. Representing Can-Fite BioPharma's venture into men's health, this compound demonstrates the company's commitment to expanding its therapeutic offerings beyond its traditional focus areas.
- Commercial Predictive Biomarker Blood Test Kit for A3AR
In addition to its pharmaceutical products, Can-Fite BioPharma is developing a commercial predictive biomarker blood test kit. This kit is designed to detect A3 adenosine receptor (A3AR) expressions, which are associated with various pathological conditions, thereby facilitating targeted therapy. It exemplifies the company's innovative approach in integrating diagnostics with therapeutics to enhance treatment efficacy.
Contact Information
